Click here for K&M Anticoagulant position statement and risk mitigation principles. NHSE updated the Commissioning recommendations for national procurement for direct-acting oral anticoagulant(s) (DOACs) on the 6th of September 2024. This document will be reviewed ASAP, via the normal ICB governance process, to reflect the current NHSE recommendations.
Click here for K&M DOAC Monitoring Recommendations for Non-Valvular Atrial Fibrillation (NVAF) in Primary Care.
Click here for NICE guidance for Atrial Fibrillation: diagnosis and management
- Vitamin K Antagonists
- Direct Oral Anticoagulants (DOACs) for DVT prophylaxis and treatment
- Direct Oral Anticoagulants (DOACs) for Non-valvular Atrial fibrillation
- Preferred
- On Formulary
- Specialist Initiation
- Hospital Use Only
- Unlicensed Medicines